A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer.
David W PookDaniel M GeynismanJoan CarlesFilippo G De BraudAnthony M JoshuaJose-Luis Perez-GraciaCasilda Llácer PérezSang Joon ShinBruno FangMinal BarveMaruzzo MarcoSergio BracardaMiso KimYannick KerloeguenJorge Daniel GalloSophia L MaundAdam HarrisKuan-Chieh HuangVictor PoonDhruvitkumar S SutariaHoward GurneyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Ipatasertib plus rucaparib was manageable with dose modification but did not demonstrate synergistic or additive antitumor activity in previously treated patients with mCRPC.